Concepedia

Author

Miles Prince

Peter MacCallum Cancer Centre

Also Known As

M Prince, M. Prince, Miles PRINCE, Miles Prince

97

Publications

1K

Citations

17

H-Index

30

Concepts

All Affiliations

Peter MacCallum Cancer CentreThe Alfred HospitalThe University of MelbourneThe University of Texas MD Anderson Cancer CenterThe Royal Melbourne Hospital
MP

About

Miles Prince is an author at Peter MacCallum Cancer Centre specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

244

2

Health Sciences

2

2

190

3

Immunology

2

2

35

4

Public Health

1

1

39

5

Epidemiology

1

1

39

Miles Prince

×

26

Publications

903

Citations

17

H-Index

YearCitations

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

Andrew Wirth, John F. Seymour, Rodney J. Hicks,

The American Journal of Medicine

2002

170

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal,

Blood

2005

114

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( <scp>PROCLIPI</scp> ) study

Kevin Molloy, Constanze Jonak, Feng Jung Sherida H. Woei-A-Jin,

British Journal of Dermatology

2019

105

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma

Piers Blombery, Ella R. Thompson, Georgina L. Ryland,

Oncotarget

2018

69

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, Robin Frye, Steven L. Allen,

Blood

2008

40

Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011

Senthil Lingaratnam, Monica A. Slavin, Bogda Koczwara,

Internal Medicine Journal

2011

39

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

Simon J. Harrison, Hang Quach, Kally Yuen,

Blood

2008

33

First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).

Andrew Spencer, Miles Prince, Andrew W. Roberts,

Blood

2006

29

An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009

Senthil Lingaratnam, Monica A. Slavin, Linda Mileshkin,

Internal Medicine Journal

2011

28

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Chanan‐Khan, Zhinuan Yu, Donna Weber,

Blood

2006

25

Page 1